Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 320

1.

S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.

Yokota T, Onozawa Y, Boku N, Hamauchi S, Tsushima T, Taniguchi H, Todaka A, Machida N, Yamazaki K, Fukutomi A, Yasui H.

Jpn J Clin Oncol. 2011 Dec;41(12):1351-7. doi: 10.1093/jjco/hyr147. Epub 2011 Oct 5.

PMID:
21980053
2.

Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer.

Suzuki S, Ishikawa K.

J Infect Chemother. 2009 Oct;15(5):335-9. doi: 10.1007/s10156-009-0712-x. Epub 2009 Oct 24.

PMID:
19856075
3.

The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.

Kim HS, Kim HR, Kim GM, Kim HS, Koh YW, Kim SH, Choi EC, Hong YK, Sung JH, Kim SM, Kim JH, Cho BC.

Cancer Chemother Pharmacol. 2012 Oct;70(4):539-46. Epub 2012 Aug 7.

PMID:
22868340
4.

Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.

Kiyota N, Tahara M, Kadowaki S, Fuse N, Doi T, Minami H, Ohtsu A.

Jpn J Clin Oncol. 2009 Apr;39(4):225-30. doi: 10.1093/jjco/hyp002. Epub 2009 Feb 10.

PMID:
19211574
5.

Outpatient chemotherapy with S-1 for recurrent head and neck cancer.

Yamashita T, Shinden S, Watabe T, Shiotani A.

Anticancer Res. 2009 Feb;29(2):577-81.

6.

Outpatient oral chemotherapy with S-1 for unresectable or distant metastatic head and neck cancer.

Maeda M, Yamashita T, Matsunobu T, Araki K, Tomifuji M, Shiotani A.

Anticancer Res. 2013 Aug;33(8):3285-9.

PMID:
23898093
7.

Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.

Peng PJ, Cheng H, Ou XQ, Zeng LJ, Wu X, Liu YM, Lin Z, Tang YN, Wang SY, Zhang HY, Chen ZB.

Drug Des Devel Ther. 2014 Aug 14;8:1083-7. doi: 10.2147/DDDT.S67592. eCollection 2014.

8.

A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy.

León X, Hitt R, Constenla M, Rocca A, Stupp R, Kovács AF, Amellal N, Bessa EH, Bourhis J.

Clin Oncol (R Coll Radiol). 2005 Sep;17(6):418-24.

PMID:
16149284
9.

Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Shin DM, Glisson BS, Khuri FR, Hong WK, Lippman SM.

Semin Oncol. 1998 Apr;25(2 Suppl 4):40-4; discussion 45-8.

PMID:
9578061
10.

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R.

N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656.

11.

A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck.

Wang TF, Chu SC, Kao RH, Yao CY, Li CC.

Jpn J Clin Oncol. 2008 Jul;38(7):459-63. doi: 10.1093/jjco/hyn052. Epub 2008 Jun 26.

PMID:
18586668
12.

Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study.

Urba S, van Herpen CM, Sahoo TP, Shin DM, Licitra L, Mezei K, Reuter C, Hitt R, Russo F, Chang SC, Hossain AM, Frimodt-Moller B, Koustenis A, Hong RL.

Cancer. 2012 Oct 1;118(19):4694-705. doi: 10.1002/cncr.27449. Epub 2012 Mar 20.

13.

Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I-II study.

Recchia F, Lalli A, Lombardo M, De Filippis S, Saggio G, Fabbri F, Rosselli M, Capomolla E, Rea S.

Cancer. 2001 Aug 15;92(4):814-21.

PMID:
11550152
14.

Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy.

Recondo G, Armand JP, Tellez-Bernal E, Domenge C, Belehradek M, De Vathaire F, Wibault P, Richard JM, Cvitkovic E.

Laryngoscope. 1991 May;101(5):494-501.

PMID:
1709437
15.

[Long-term results of S-1 administration as adjuvant chemotherapy for advanced head and neck cancer].

Tsukuda M, Kida A, Fujii M, Kono N, Yoshihara T, Hasegawa Y, Sugita M.

Gan To Kagaku Ryoho. 2007 Aug;34(8):1215-25. Japanese.

PMID:
17687202
16.

Consecutive daily low-dose S-1 adjuvant chemotherapy after radical treatment for squamous cell carcinoma in head and neck cancer.

Furusaka T, Tanaka A, Matsuda H, Ikeda M.

Acta Otolaryngol. 2011 Oct;131(10):1099-103. doi: 10.3109/00016489.2011.590153. Epub 2011 Jun 8.

PMID:
21651316
17.

Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.

Yao M, Dornfeld KJ, Buatti JM, Skwarchuk M, Tan H, Nguyen T, Wacha J, Bayouth JE, Funk GF, Smith RB, Graham SM, Chang K, Hoffman HT.

Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):410-21.

PMID:
16168834
18.

Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy.

Hosokawa A, Sugiyama T, Ohtsu A, Doi T, Hattori S, Kojima T, Yano T, Minashi K, Muto M, Yoshida S.

J Gastroenterol. 2007 Jul;42(7):533-8. Epub 2007 Jul 25.

PMID:
17653648
19.

Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer.

Fujii M, Tomita K, Nishijima W, Tsukuda M, Hasegawa Y, Ishitoya J, Yamane H, Homma A, Tomita T.

Jpn J Clin Oncol. 2010 Mar;40(3):214-21. doi: 10.1093/jjco/hyp153. Epub 2009 Nov 23.

PMID:
19934112
20.

[Late phase II study of S-1 in patients with advanced head and neck cancer].

Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B; S-1 Cooperative Study Group (Head and Neck Cancer Working Group).

Gan To Kagaku Ryoho. 2001 Oct;28(10):1381-90. Japanese.

PMID:
11681245

Supplemental Content

Support Center